GL Pharm Tech to Absorb Wholly-Owned Subsidiary GL Pharma
지엘팜텍
204840
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=654
Risk-adjusted indicator based on 654 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Merger Ratio: 1.0000000 (GL Pharm Tech) : 0.0000000 (GL Pharma)
- • GL Pharma 2025 Revenue: 21.19B KRW
- • GL Pharma 2025 Operating Profit: 1.02B KRW
- • GL Pharma 2025 Net Income: 628.41M KRW
- • GL Pharm Tech's Stake in GL Pharma: 100%
AI Analysis Summary
GL Pharm Tech Corp. has decided to absorb its wholly-owned subsidiary, GL Pharma Co., Ltd., through a small-scale, non-capital increase merger. The merger ratio is 1.0000000:0.0000000, with no new shares or cash payouts. GL Pharma reported 2025 revenue of 21.19B KRW, operating profit of 1.02B KRW, and net income of 628.41M KRW. This internal restructuring aims to enhance management efficiency and is not expected to have a significant financial or operational impact on GL Pharm Tech, as it already owns 100% of GL Pharma. The merger is scheduled for July 31, 2026.
How This Event Is Evaluated
M&A / Merger Evaluation
M&A events are evaluated by assessing deal size relative to company scale, strategic rationale, financing structure, and integration risk.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Deal size relative to market value
- Strategic fit and synergy potential
- Financing structure (cash, stock, debt)
- Regulatory and integration risk
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.